# Adult Subjects With Uncontrolled Type 2 Diabetes

Study · id `cardio:ct-nct02317796` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02317796](<https://clinicaltrials.gov/study/NCT02317796>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02317796

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 149 participants.

## Technical summary

Registry record NCT02317796. Randomized; triple masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2015-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 149 participants (enrolled count; ClinicalTrials.gov record NCT02317796, source copy `cardio:ctgov-nct02317796-2016-09-26`, retrieved 2026-10-26)
- Start date: 2014-12 (registry gives no type) (ClinicalTrials.gov record NCT02317796, source copy `cardio:ctgov-nct02317796-2016-09-26`, retrieved 2026-10-26)
- Primary completion: 2015-12 (actual) (ClinicalTrials.gov record NCT02317796, source copy `cardio:ctgov-nct02317796-2016-09-26`, retrieved 2026-10-26)
- Completion: 2016-02 (actual) (ClinicalTrials.gov record NCT02317796, source copy `cardio:ctgov-nct02317796-2016-09-26`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02317796, source copy `cardio:ctgov-nct02317796-2016-09-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02317796-2016-09-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Adult Subjects With Uncontrolled Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): MLR-1023
- Lead sponsor: Melior Pharmaceuticals
- Lead sponsor class: OTHER
- Collaborator: Bukwang Pharmaceutical, Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus (`cardio:pubmed-32019723`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 13f5211840e8b6324adc83952cff1695ccdcf0553dc02c2c6703812793c76cd8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
